Ora has a proven track record of 19 anti-allergic product approvals from the FDA, EMA, and PMDA over the past 40 years
The development of the next generation of anti-allergic bio-pharmaceuticals will rely on the ability to define the proper clinical and regulatory pathways, coupled with a precise understanding of the proper endpoints, timepoints, and therapy mechanics. At Ora, our approach is to tighten standard deviations through an enhanced level of scientific rigor, the addition of objective assessments, and stringent controls in our models. We study the underlying science of allergic disease, with a specific focus on how potential therapeutic agents may benefit our patients.
Let’s connect! Please fill out the below form or call us at +1 978-685-8900